BD5-2d (ATCC® HB-9689)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphoblast B lymphocyte; somatic cell hybri  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphoblast B lymphocyte; somatic cell hybri
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Strain

Strain: BALB/c (B cell); BALB/c (myeloma)

Applications
Animals were immunized with a transfected NIH 3T3 cell line, 18-3-7 that expresses full length normal human neu protein.
Storage Conditions liquid nitrogen vapor phase
Images
Derivation
Animals were immunized with a transfected NIH 3T3 cell line, 18-3-7 that expresses full length normal human neu protein. Spleen cells were fused with SP2/O myeloma cells (ATCC CRL 1581). The antibody recognizes substantially purified p100, human neu related protein, the full-length HER-2/neu molecule in tumor tissue (p185) or the extracellular domain (ECD) (p105) in serum, plasma, cell cultures and fluids.
Comments
Animals were immunized with a transfected NIH 3T3 cell line, 18-3-7 that expresses full length normal human neu protein. Spleen cells were fused with SP2/O myeloma cells (ATCC CRL 1581). The antibody recognizes substantially purified p100, human neu related protein, the full-length HER-2/neu molecule in tumor tissue (p185) or the extracellular domain (ECD) (p105) in serum, plasma, cell cultures and fluids.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 X 10(4) viable cells/ml. Do not allow the cell concentration to reach. 1 X 10(6) cells/ml.
Interval: Maintain cultures at a cell concentration between 6 x 10(4) and 6 X 10(5) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with 7.5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype mouse IgG1 kappa
Name of Depositor Applied Biotechnology, Inc
References

Carney WP, McKenzie SJ. Detection and quantification of neu related proteins in the biological fluids of humans. US Patent 5,401,638 dated Mar 28 1995

Carney WP, et al. Detection of neu p185 in cell lysates. US Patent 5,604,107 dated Feb 18 1997

McKenzie SJ, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4: 543-548, 1989. PubMed: 2566965

Animals were immunized with NIH/3T3 cells expressing full-length human HER-2/neu protein.

Weinberg RA, et al. Oncogenes and methods for their detection. U.S. Patent 6,713,619 dated Mar 30 2004

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Carney WP, McKenzie SJ. Detection and quantification of neu related proteins in the biological fluids of humans. US Patent 5,401,638 dated Mar 28 1995

Carney WP, et al. Detection of neu p185 in cell lysates. US Patent 5,604,107 dated Feb 18 1997

McKenzie SJ, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4: 543-548, 1989. PubMed: 2566965

Animals were immunized with NIH/3T3 cells expressing full-length human HER-2/neu protein.

Weinberg RA, et al. Oncogenes and methods for their detection. U.S. Patent 6,713,619 dated Mar 30 2004